100 results about "Antigen Targeting" patented technology

The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.

The invention relates to a detection kit for diagnosing tuberculosis, comprising a recombinant antigenic protein, wherein the recombinant antigenic protein is the fusion protein obtained by connecting ESAT-6 (early secreting antigen target 6KD), CFP-10 (cultufiltrate protein 10KD), and MPB64 (Mycobacterium bovis 64KD) by connecting peptides according to an arbitrary sequence, wherein the connecting peptides are short peptides which do not influence the immunogenicity of ESAT-6, CFP-10 and MPB64. Preferably, the recombinant antigenic protein in the detection kit for diagnosing tuberculosis is the antigenic protein with an amino acid sequence which is SEQ ID: No.1. When the detection kit in the invention is used for diagnosing tuberculosis, the diagnosis time is short, the diagnosis is fast, the sensitivity is strong, and the specificity is high; and the detection kit has an important significance on early diagnosis of tuberculosis.

The invention discloses a preparation method for a single-chain antibody based on a hybridoma cell. The preparation method comprises the following steps: carrying out inverse transcription with total mRNA of the hybridoma cell as a template to obtain cDNA and selecting and using universal primers with low degeneracy for amplification of a complete set of heavy chain variable region and light chain variable region genes of the antibody; inputting sequences of the amplified heavy chain and light chain variable region genes into an IMGT database for analysis and eliminating antibody genes and nonsense genes originated from the hybridoma cell so as to obtain candidate heavy chain and light chain variable region genes; translating the genes into amino acid sequences, carrying out three dimensional structural homology modeling to obtain a three dimensional simulation structure of the single-chain antibody and carrying out molecular docking analysis on the three dimensional simulation structure and a corresponding antigen target molecule; and splicing a candidate heavy chain and a candidate light chain with correct analysis results into a single-chain antibody gene by using an overlap extension PCR method and carrying out expression and identification of antibody activity. The preparation method provided by the invention is applicable to preparation of all the single-chain antibodies originated from monoclonal hybridoma cells; the process of the preparation method is simple and rapid, and a prepared product has high quality.

The invention discloses a gene for encoding anti-BCMA chimeric antigen receptor. The nucleotide sequence of the gene is represented by SEQ ID NO:2. The invention also discloses a recombinant expression vector containing the gene, and a myeloma BCMA antigen-targeted transgenic T cell. The transgenic T-cell is a primitive cell containing the recombinant expression vector and knocked out of a PD1 gene or/and a CTLA4 gene, or is a primitive cell with the chromosome being integrated with the gene for encoding anti-BCMA chimeric antigen receptor and knocked out of tbe PD1 gene or/and the CTLA4 gene.A preparation method of the transgenic T-cell comprises the following steps: mixing of gRNA, CRISPR-cas9 mRNA and HDR mix, and electrotransformation recombination of the T cell. The invention furtherdiscloses an application of the myeloma BCMA antigen-targeted transgenic T cell in the preparation of drugs for treating multiple myeloma. In the construction process of carT of, a recognition sequence of EGFR is introduced, EGFR monoclonal antibody Cetuximab is used to eliminate a carT cell if necessary, and PD1 and CTLA4 genes are knocked out to relieve the inhibition effect of the PD1 and CTLA4 genes on the carT cell and enhance the overcoming effect of the carT cell on the inhibition of the tumor microenvironment on immune cell functions.

The invention discloses a construction method and an application of a lentiviral vector for expressing a TGF-beta antibody as well as a construction method and an application of a CAR-T cell based onthe problem that immunosuppression molecules and suppressor cells are the biggest barriers in the treatment of solid tumors in a tumor immunosuppression microenvironment, relating to the technical field of tumor immunotherapy. The invention discloses the lentiviral vector which carries a CAR gene of a solid tumor specific antigen target spot of the TGF-beta antibody as well as the CAR-T cell for expressing the solid tumor specific antigen target spot of the TGF-beta antibody. The construction methods and the application have the beneficial effects that the targeting effect on the tumor cells is realized, the suppressor cells in the tumor microenvironment are reduced, the solid tumors are killed to an extreme extend, and the new breakthrough on the immunotherapy of the solid tumors is realized.

The invention is applicable to the technical field of biology, and provides a B cell linear epitope of a novel coronavirus S protein, an antibody, an identification method and an application, and theamino acid sequence of the B cell linear epitope of the S protein is shown as SEQ ID NO.104 or SEQ ID NO.82. The invention provides a brand-new B cell linear epitope of the novel coronavirus S protein, which can be used for detecting a specific antibody in blood of a COVID-19 patient, and can also be used for being inoculated into healthy people to induce generation of the specific antibody, so that an important antigen target is provided for design of an SARS-CoV-2 vaccine, research and development of the monoclonal antibody and research and development of an antibody detection kit.

The invention provides a prostate-specific antigen targeting inhibitor of a nuclide marker. The targeting inhibitor is DKFZ-PSMA-617 of a radioactive nuclide marker. Radioactive nuclide includes at least one of 64Cu, 68Ga and 89Zr. The invention further provides a preparation method of the nuclide marker DKFZ-PSMA-617. The nuclide marker DKFZ-PSMA-617 is stable in property and good in development effect, has high affinity and functional activity on PSMA, is beneficial to diagnosis and accurate staging of early prostate cancer, and provides a new thought for diagnosis of breast cancer and gastric adenocarcinoma. Further preclinical animal level research proves that the inhibitor is expected to become a targeting PSMA developing agent and a tumor treatment agent with good application prospects.

The invention provides a recombinant Newcastle disease virus vector containing a novel coronavirus double-antigen target sequence combination and a corresponding vaccine strain and a vaccine, and relates to the technical field of biological medicines. According to the invention, an NDV vector, a novel coronavirus S protein gene and an S protein receptor binding domain RBD gene are used as antigen sequences, the S protein gene and the RBD gene are jointly inserted into an NDV genome, and a virus reverse genetics technology is utilized to rescue and obtain the vaccine strain with the infectious NDV virus limiting vector. The vaccine strain can be recognized by respiratory tract cells to generate mucosal immunity and infect the cells, so that the specific immune antibody level is increased. By introducing the double-antigen target, the immunogenicity of the vaccine strain is enhanced, the toxic and side effects of the vaccine strain are reduced, and the immune effect is better than that of a single-target antigen.

An antigen-specific T-cell response to alloantigen, tissue-specific antigen (e.g., islet antigen or other autoantigens involved in autoimmune disease), or self (or host) antigen is detected at an early stage of graft rejection or recurrent autoimmunity. An increase in cytotoxic lymphocyte gene (CLG) expression in peripheral blood is a risk factor for development of deleterious immune responses, which may be confirmed by functional assays. For example, the distinction between production of regulatory or inflammatory cytokines by T cells may dissect the type of immune response which is being induced: the survival of transplanted islet cells used to treat type 1 diabetes may be monitored, loss of the transplant by graft rejection (i.e., an alloantigen target) may be distinguished from autoimmune disease (i.e., a self or host antigen target).

The invention relates to a double chimeric antigen receptor gene-modified immune cell based on CD19 and BCMA and application thereof. A double chimeric antigen receptor comprises a chimeric antigen receptor CD19 and a chimeric antigen receptor BCMA. The chimeric antigen receptor is formed by connecting an antigen binding domain, a trans-membrane domain, a co-stimulatory signal conduction region, aCD3 zeta signal conduction domain and an inducible suicide fusion domain in series. The chimeric antigen receptor can specifically recognize tumor surface antigens CD19 and BCMA; and compared with the use of other mono-chimeric antigen receptor T cells, the combined use of two antigen-targeted CAR-T cells ensures that the treatment effect is better, the CD19 escape is hard to occur, and diseasesare more easily alleviated.

The invention discloses a lentiviral vector expressing a CD40 antibody, and a construction method and application of CAR-T cells, and relates to the technical field of tumor immunotherapy. The lentiviral vector expressing the CD40 antibody, and the construction method and application of the CAR-T cells are put forward based on the problem that macrophages promote tumor deterioration. The lentiviral expression vector carrying CAR genes of solid tumor specific antigen target spots of the CD40 antibody, and the CAR-T cells expressing the solid tumor specific antigen target spots of the CD40 antibody are included. The lentiviral vector expressing the CD40 antibody, and the construction method and application of the CAR-T cells have the beneficial effects that the adverse effects that T cells for identifying a certain antigen by relying on TCR proliferate in quantity, and inflammation is likely to be caused are solved, and it is ensured that the CAR-T cells can exert the tumor killing capacity specifically and exclusively.

The present invention belongs to the field of biotechnology, and relates to a surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment, encoded gene and use thereof. According to the invention, the surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is filtered from a base through establishing a Toxoplasma gondii human immunoglobulin, ELISA, diluting the prothrombin time, sequencing analysis, etc. Through expression purifying and authenticating, the human antigen Fab fragment is authenticated to specifically identify the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii and have higher affinity with the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii, for being identified with the specificity of Toxoplasma gondii tachyzoite-bradyzoite. The human antigen Fab fragment of the invention does not contain Fc segment and does not activate the alexin or cause the histopathological damages of human immune response, etc. when the function of restricting the invasion of Toxoplasma gondii to the host cell is exerted. The surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is safe and reliable when applied for the human body. The antigen medicine for treating toxoplasmosis or the antigen targeted medicine can be prepared.

The invention provides A-type foot-and-mouth disease targeting composite epitope protein mediated by pig chemotactic factors.The amino acid sequence of the protein is as shown in SEQ ID No.2 in a sequence list.The invention further provides a vaccine with the pig A-type foot-and-mouth disease targeting composite epitope protein.An FMDV specific antibody can be detected one week after an animal is immunized by the vaccine, and the valence of the antibody is continuously improved and reaches the highest four weeks after immunization.After 1000 pigs of the HNXX strain of the A/SEA/97 series of the pig media infective dose (PID50) adapt to toxin attack, the pigs in the vaccine immunity group can all completely resist strong toxin attack, and no pigs present clinical symptoms within 10 days after toxin attack.It is shown that after an A8 antigen targets an XCR1 receptor through XCL1 and dendritic cells are activated by CpG, the body fluid immunity and cell immunity level of the antigen can be remarkably improved, and thus the vaccine is an effective vaccine with the A-type foot-and-mouth disease targeting composite epitope protein mediated by pig chemotactic factors.

The invention discloses a chimeric antigen receptor and an application thereof in preparation of a product for treatment of tumors. The chimeric antigen receptor sequentially comprises a lead peptide,an anti-LILRB4 single-chain antibody, a human CD8 hinge transmembrane region, a human 4-1BB intracellular region, a human CD3 zeta intracellular region, a self-cleaving peptide and human IFN full length. A new generation of CAR-T cell treatment product is designed and developed by using LILRB4 as an antigen target for the first time, and a gene-optimized human full-length interferon (IFN) fragment is added to the C terminal of the LILRB4-CAR. Compared with a CAR-T cell which only expresses the LILRB4-CAR, the CAR-T cell which expresses the LILRB4-CAR-IFN has higher tumor killing capacity, andthe safety and effectiveness of the CAR-T cell in tumor treatment are further improved.

The invention provides a monoclonal antibody TBEF3 of tubercle bacillus-resistant secretory antigen target protein in early stage. The monoclonal antibody TBEF3 is prepared by the following steps: selecting a specific antigen peptide mouse; collecting sensitized mouse B lymphocyte and mouse myeloma cell to fuse; judging positive clones by using an enzyme linked immunosorbent assayelisa and an immunoblotting testing method; establishing a hybridoma cell line TBEF3 for secreting monoclonal antibody of tubercle bacillus-resistant secretory ESAT-6 in early stage; carrying out multiplication culturing on the positive cells and injecting to congenic mouse enterocoelia for induction of generation of ascitic fluid containing antibody; and carrying out collection and antibody affinity purification to obtain the monoclonal antibody TBEF3 of tubercle bacillus-resistant secretory antigen target protein in early stage. The invention also provides an application of the monoclonal antibody in testing the secretory antigen target protein of mycobacterium tuberculosis in early stage.

The invention relates to a method for modifying a bird flu virus through interferon inducible protein ESAT6, which adopts an early secretory antigen target ESAT-6 gene of mycobacterium tuberculosis to modify the bird flu virus and is a method for splicing into an exogenous DNA on the basis of establishing a bird flu virus reverse genetic operating system. The selected ESAT-6 protein is secretory protein with a T cell multifunctional epiposition and has the main function of stimulating an organism to generate IFN, which has uniqueness in researching a virus anti-infective immune mechanism path. After a bird flu virus gene is modified through the DNA, when the modified virus is rescued, not only the transcription, the translation and the virus packaging of bird flu virus protein are not influenced, but also the ESAT-6 protein can be simultaneously generated.

The invention relates to the technical field of immunization, and especially relates to a fusion protein antibody, an enhanced vaccine and a preparation method and an application thereof. The fusion protein antibody provided by the present invention comprises a secretion peptide, a targeting antigen, a connecting peptide, and a CD317-specific antibody. The CD317 as an antigen to target the delivery targets has more advantages that: 1) the expression level is higher and can be further induced up-regulated by IFN to form a benign feedback loop; and 2) the antigen presentation is more efficient and can activate the stronger specific immune response. Due to the high efficiency of antigen presentation, the amount of vaccine used can be reduced and the cost can be reduced. As the therapeutic vaccine, the ability to activate an immune response is stronger than that of a soluble non-targeting antigen under development. The experiments of the present invention show that the antibody provided bythe invention can significantly promote the division of spleen cells, promote the secretion of IFN-gamma, and improve the killing ability of mouse spleen cells to target cells.

The invention provides a chimeric receptor. The chimeric receptor comprises (1) an extracellular recognition domain of an Fc fragment; (2) an extracellular spacer region; (3) a transmembrane area; (4) an intracellular signaling domain; optionally, the chimeric receptor further comprises (5) one or more co-stimulatory signaling domains and/or (6) one or more cytokine receptor signaling domains. The invention also provides an immune cell expressing the chimeric receptor. The invention also provides a combination comprising the immune cell and a tumor antigen targeting antibody or a viral antigen targeting antibody. The brand-new Fc fragment high-affinity chimeric receptor provided by the invention has higher antibody Fc fragment affinity, and can remarkably enhance ADCC effect when being used in combination with a tumor antigen targeting antibody or a virus antigen targeting antibody.